

Laurence J Egan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2462758/publications.pdf>

Version: 2024-02-01

57
papers

6,125
citations

159358

30
h-index

182168

51
g-index

58
all docs

58
docs citations

58
times ranked

8451
citing authors

#	ARTICLE	IF	CITATIONS
1	Inflammation-specific targeted carriers for local drug delivery to inflammatory bowel disease. <i>Biomaterials</i> , 2022, 281, 121364.	5.7	37
2	Subtotal colectomy in ulcerative colitis – long term considerations for the rectal stump. <i>World Journal of Gastrointestinal Surgery</i> , 2021, 13, 198-209.	0.8	7
3	Endoscopy Capsule Retention in a Young Female with Small Bowel Strictures Secondary to Non-Steroidal Anti-Inflammatory Drugs. <i>Case Reports in Gastroenterology</i> , 2021, 15, 948-953.	0.3	1
4	The pseudo-caspase FLIP(L) regulates cell fate following p53 activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 17808-17819.	3.3	18
5	Irish data on the safety and efficacy of vedolizumab in the treatment of inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 786-794.	0.6	2
6	Comparison of medium to long-term outcomes of acute severe ulcerative colitis patients receiving accelerated and standard infliximab induction. <i>Frontline Gastroenterology</i> , 2020, 11, 441-447.	0.9	6
7	Protocol for a multicentred randomised controlled trial investigating the use of personalised golimumab dosing tailored to inflammatory load in ulcerative colitis: the GOAL-ARC study (GLM dose) Tj ETQq1 1 0,784314 rgBT /Ov	1.1	9
8	Stromal Cell PD-L1 Inhibits CD8+ T-cell Antitumor Immune Responses and Promotes Colon Cancer. <i>Cancer Immunology Research</i> , 2018, 6, 1426-1441.	1.6	66
9	Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 1019-1026.	0.8	9
10	Inflammation-associated DNA methylation patterns in epithelium of ulcerative colitis. <i>Epigenetics</i> , 2017, 12, 591-606.	1.3	40
11	Ten Years of the Journal of Crohn's and Colitis. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1029-1029.	0.6	0
12	Infliximab Selectively Modulates the Circulating Blood Monocyte Repertoire in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2863-2878.	0.9	8
13	Differential DNA methylation patterns of homeobox genes in proximal and distal colon epithelial cells. <i>Physiological Genomics</i> , 2016, 48, 257-273.	1.0	6
14	Mesenchymal stromal cells (MSCs) and colorectal cancer: a troublesome twosome for the anti-tumour immune response?. <i>Oncotarget</i> , 2016, 7, 60752-60774.	0.8	56
15	New Insights into the Mechanisms of Action of Anti-Tumor Necrosis Factor- α Monoclonal Antibodies in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2909-2920.	0.9	42
16	The intestinal epithelial cell cycle. <i>Current Opinion in Gastroenterology</i> , 2015, 31, 124-129.	1.0	16
17	European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 945-965.	0.6	328
18	Taking a closer look at IBD. <i>Gut</i> , 2014, 63, e1-e1.	6.1	0

#	ARTICLE	IF	CITATIONS
19	A new hand on the tiller: Taking over the editorship of the Journal of Crohn's and Colitis. Journal of Crohn's and Colitis, 2014, 8, 91-92.	0.6	0
20	Corrigendum to "Optimising monitoring in the management of Crohn's disease: A physician perspective" [Journal of Crohn's and Colitis volume 7 (2013) 653-669]. Journal of Crohn's and Colitis, 2014, 8, 441.	0.6	0
21	Non-colorectal intestinal tract carcinomas in inflammatory bowel disease: Results of the 3rd ECCO Pathogenesis Scientific Workshop (II). Journal of Crohn's and Colitis, 2014, 8, 19-30.	0.6	61
22	Optimising monitoring in the management of Crohn's disease: A physician's perspective. Journal of Crohn's and Colitis, 2013, 7, 653-669.	0.6	96
23	Gastrointestinal radiation injury: Prevention and treatment. World Journal of Gastroenterology, 2013, 19, 199.	1.4	111
24	Gastrointestinal radiation injury: Symptoms, risk factors and mechanisms. World Journal of Gastroenterology, 2013, 19, 185.	1.4	190
25	Inflammation, DNA methylation and colitis-associated cancer. Carcinogenesis, 2012, 33, 723-731.	1.3	144
26	Mechanisms of Drug Toxicity or Intolerance. Digestive Diseases, 2011, 29, 172-176.	0.8	6
27	Autophagosomal β -Degradation Plays a Role in the Long Term Control of Tumor Necrosis Factor- α -induced Nuclear Factor- κ B (NF- κ B) Activity. Journal of Biological Chemistry, 2011, 286, 22886-22893.	1.6	57
28	Upregulation of DNA Methyltransferase-Mediated Gene Silencing, Anchorage-Independent Growth, and Migration of Colon Cancer Cells by Interleukin-6. Molecular Cancer Research, 2010, 8, 471-481.	1.5	139
29	Is There a Role for Nuclear Factor κ B in Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance?. Annals of the New York Academy of Sciences, 2009, 1171, 38-49.	1.8	19
30	Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial. Gastrointestinal Endoscopy, 2008, 68, 255-266.	0.5	333
31	Nitric oxide promotes endothelial cell survival signaling through S-nitrosylation and activation of dynamin-2. Journal of Cell Science, 2007, 120, 492-501.	1.2	113
32	A Nudge in the Right Direction: Shaping the Metabolic Fate of Thiopurines for Therapeutic Gain. Clinical Gastroenterology and Hepatology, 2007, 5, 170-171.	2.4	0
33	Allopurinol and 6MP: Steering through the therapeutic obstacle course. Inflammatory Bowel Diseases, 2007, 13, 1312-1313.	0.9	1
34	Gastroesophageal reflux disease in pregnancy. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2007, 21, 793-806.	1.0	147
35	Pharmacogenomics in Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2006, 4, 21-28.	2.4	30
36	The AmpliChip CYP450 Test: Principles, Challenges, and Future Clinical Utility in Digestive Disease. Clinical Gastroenterology and Hepatology, 2006, 4, 822-830.	2.4	22

#	ARTICLE	IF	CITATIONS
37	Budesonide in the treatment of inflammatory bowel disease: The first year of experience in clinical practice. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 29-32.	0.9	49
38	NF- κ B Signaling: Pros and Cons of Altering NF- κ B as a Therapeutic Approach. <i>Annals of the New York Academy of Sciences</i> , 2006, 1072, 114-122.	1.8	42
39	Antiankirs Effect of Nuclear Factor- κ B through Up-regulated Expression of Osteoprotegerin, BCL-2, and IAP-1. <i>Journal of Biological Chemistry</i> , 2006, 281, 8686-8696.	1.6	48
40	Endoscopic Factors in the Diagnosis of Colorectal Dysplasia in Chronic Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2005, 11, 428-434.	0.9	48
41	Acute Pancreatitis in Patients With Crohn's Disease: Clinical Features and Outcomes. <i>Inflammatory Bowel Diseases</i> , 2005, 11, 1080-1084.	0.9	53
42	Positioning novel biologic, probiotic, and apheresis therapies for crohn's disease and ulcerative colitis. <i>Current Gastroenterology Reports</i> , 2005, 7, 485-491.	1.1	4
43	Selective Inhibition of Inflammatory Gene Expression in Activated T Lymphocytes: A Mechanism of Immune Suppression by Thiopurines. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 312, 537-545.	1.3	115
44	I κ B-kinase-dependent NF- κ B activation provides radioprotection to the intestinal epithelium. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 2452-2457.	3.3	185
45	Expression of Epstein-Barr virus-induced gene 3 and other interleukin-12-related molecules by human intestinal epithelium. <i>Immunology</i> , 2004, 112, 437-445.	2.0	36
46	Drug interactions in gastroenterology: Mechanisms, consequences, and how to avoid. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 725-730.	2.4	4
47	IKK β Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer. <i>Cell</i> , 2004, 118, 285-296.	13.5	2,277
48	The two faces of IKK and NF- κ B inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. <i>Nature Medicine</i> , 2003, 9, 575-581.	15.2	506
49	AZATHIOPRINE DOWNREGULATES TRAIL EXPRESSION IN A T CELL LINE AND IN NORMAL HUMAN PERIPHERAL BLOOD T CELLS. <i>American Journal of Gastroenterology</i> , 2003, 98, S256.	0.2	0
50	Role of EHEC O157:H7 virulence factors in the activation of intestinal epithelial cell NF- κ B and MAP kinase pathways and the upregulated expression of interleukin 8. <i>Cellular Microbiology</i> , 2002, 4, 635-648.	1.1	141
51	New Perspectives in Gastric Acid Suppression: Genetic Polymorphisms Predict the Efficacy of Proton Pump Inhibitors. <i>Digestive Diseases</i> , 2000, 18, 58-63.	0.8	12
52	Clinical outcome and pharmacokinetics after addition of low-dose cyclosporine to methotrexate: A case study of five patients with treatment-resistant inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2000, 6, 286-289.	0.9	11
53	Inhibition of Interleukin-1-stimulated NF- κ B RelA/p65 Phosphorylation by Mesalamine Is Accompanied by Decreased Transcriptional Activity. <i>Journal of Biological Chemistry</i> , 1999, 274, 26448-26453.	1.6	195
54	Plasma and Rectal Adenosine in Inflammatory Bowel Disease: Effect of Methotrexate. <i>Inflammatory Bowel Diseases</i> , 1999, 5, 167-173.	0.9	17

#	ARTICLE	IF	CITATIONS
55	Clinical Outcome Following Treatment of Refractory Inflammatory and Fistulizing Crohn's Disease With Intravenous Cyclosporine. American Journal of Gastroenterology, 1998, 93, 442-448.	0.2	171
56	Methotrexate for Inflammatory Bowel Disease: Pharmacology and Preliminary Results. Mayo Clinic Proceedings, 1996, 71, 69-80.	1.4	82
57	Celiac Disease and T-Cell Lymphoma. New England Journal of Medicine, 1996, 335, 1611-1612.	13.9	8